Brian Piekos serves as the Chief Financial Officer at KalVista Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on developing innovative therapies for hereditary angioedema and other diseases. In this role, he oversees all financial operations, including strategic planning, budgeting, investor relations, and compliance, playing a pivotal part in guiding the company's growth and financial health. With a keen eye for fiscal strategy, Piekos has been instrumental in securing funding rounds and managing capital allocation to support KalVista's pipeline of oral protease inhibitors, ensuring the company remains agile in the competitive biotech landscape. Prior to joining KalVista in 2020, Piekos built a robust career in finance within the life sciences sector. He held senior positions at several prominent biotech firms, including as Vice President of Finance at a leading oncology-focused company, where he managed multimillion-dollar budgets and led successful IPO preparations. His expertise in mergers and acquisitions was evident in orchestrating key deals that expanded company portfolios and enhanced shareholder value. Piekos holds an MBA from Harvard Business School and a bachelor's degree in economics from the University of Pennsylvania, credentials that have underpinned his analytical approach to financial leadership. Throughout his tenure at KalVista, Piekos has achieved notable milestones, such as navigating the company through challenging market conditions while advancing clinical trials and partnerships. His contributions have not only strengthened KalVista's financial foundation but also fostered a culture of transparency and innovation. Outside of his professional duties, Piekos is an advocate for financial literacy in the biotech industry, often speaking at conferences on sustainable growth strategies for emerging pharma companies.